Regenxbio to receive $370 mln upfront in gene therapy deal with AbbVie [Financial Post (Toronto, Ontario, Canada)]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Financial Post
Shares of the Regenxbio, which could potentially receive up to $1.38 billion in milestone payments, jumped 26% to $41.75. 19 best online deals in the Canadian retail space right now Advertisement Regenxbio is currently testing RGX-314, administered under the retina, in a large trial as a one-time treatment for wet age-related macular degeneration (AMD). Wet AMD is a disorder that causes blurred vision. Advertisement Article content The company plans to start a second trial by the end of the year, which would support its U.S. marketing application in 2024. AbbVie acquired a range of U.S.-approved eye drugs through a $63 billion Allergan deal that closed last year. These include, Acular and Acuvail, which are used to treat inflammation following cataract surgery, and the Durysta implant to reduce eye pressure in patients with glaucoma. “We chose to partner with AbbVie, certainly due to their strength and their global commercialization reach and the fact that they have one
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsPR Newswire
- Coave Therapeutics Showcases its ALIGATER™ Platform for Generating Conjugated AAV (coAAV) Vectors Exhibiting Superior Performance in Delivering Ocular Gene Therapy through the Suprachoroidal Route [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPR Newswire
RGNX
Earnings
- 2/27/24 - Miss
RGNX
Sec Filings
- 4/17/24 - Form 4
- 4/4/24 - Form ARS
- 4/4/24 - Form DEFA14A
- RGNX's page on the SEC website